#cr845

Cara Therapeutics Stock Could atomize Out on IV CR845 Data – Investopedia

[ad_1] Cara Therapeutics, Inc. (CARA) has risen more than 14% this week after reporting an interim update on its Phase III clinical trial of IV CR845. Investors were initially disappointed that the drug has yet to achieve its primary endpoint, but both doses were well tolerated, and the clinical trial is expected to finish by the fourth quarter of this year. Shares quickly recovered from their…

Difelikefalin, CR-845; MR-13A-9; MR-13A9 4-amino-1- (D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl) piperidine-4-carboxylic acid Phase III C36H53N7O6, 679.40573 Originator Ferring Pharmaceuticals Developer Cara Therapeutics Class Analgesic drugs (peptides) Mechanism Of Action Opioid kappa receptor agonists Who Atc Codes D04A-X (Other antipruritics), N02A (Opioids) Ephmra Codes D4A…

Difelikefalin, CR-845; MR-13A-9; MR-13A9

4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid

Phase III

C36H53N7O6, 679.40573

Originator Ferring Pharmaceuticals Developer Cara Therapeutics Class Analgesic drugs (peptides) Mechanism Of Action Opioid kappa receptor agonists Who Atc Codes D04A-X (Other antipruritics), N02A (Opioids) Ephmra Codes D4A…